HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

antimicrobial peptide IB-367 (iseganan)

a structural analog of protegrin-1; reduces the local microflora densities & may improve clinical outcomes in patients at risk for the development of oral mucositis
Also Known As:
iseganan; IB-367
Networked: 29 relevant articles (8 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Cirioni, Oscar: 6 articles (05/2014 - 11/2003)
2. Kamysz, Wojciech: 6 articles (05/2014 - 11/2003)
3. Giacometti, Andrea: 5 articles (05/2014 - 11/2003)
4. Orlando, Fiorenza: 4 articles (05/2014 - 11/2003)
5. Ghiselli, Roberto: 4 articles (05/2014 - 11/2003)
6. Silvestri, Carmela: 3 articles (05/2014 - 11/2007)
7. Scalise, Giorgio: 3 articles (11/2007 - 11/2003)
8. Fuchs, Henry: 3 articles (01/2006 - 07/2003)
9. Fleming, Thomas R: 3 articles (01/2006 - 07/2003)
10. Redman, Rebecca: 3 articles (06/2004 - 08/2002)

Related Diseases

1. Stomatitis
2. Pain (Aches)
3. Infection
4. Mucositis
5. Neoplasms (Cancer)
01/01/2006 - "The drug has shown little resistance in vitro and to be safe and well tolerated in 800 patients with cancer treated for up to 6 wk. To determine the efficacy of iseganan for the prevention of ventilator-associated pneumonia (VAP). "
01/01/2000 - "Based on the SAR studies, and on the microbiological data from an animal model, one protegrin analogue, IB-367, was selected for clinical development as a topical agent to prevent the oral mucositis associated with cancer therapy."
06/01/2004 - "This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol; Valganciclovir hydrochloride, val-mCyd, vardenafil hydrochloride hydrate, vinflunine, voriconazole; Ximelagatran, XTL-002; Yttrium 90 (90Y) ibritumomab tiuxetan."

Related Drugs and Biologics

1. linezolid (Zyvox)
2. Daptomycin
3. Teicoplanin
4. Methicillin (Metin)
5. Escherichia coli 0111 B4 lipopolysaccharide
6. Anti-Bacterial Agents (Antibiotics)
7. Uperoleia mjobergii uperin 3.6 peptide
8. temporin
9. pexiganan
10. Fibroblast Growth Factor 7

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Radiotherapy
3. Catheters
4. Transplants (Transplant)
5. Intraperitoneal Injections